Chimpanzee-origin adenovirus vectors as vaccine carriers

✍ Scribed by Tatsis, N; Tesema, L; Robinson, E R; Giles-Davis, W; McCoy, K; Gao, G P; Wilson, J M; Ertl, H C J

• Book ID: 110039729
• Publisher: Nature Publishing Group
• Year: 2005
• Tongue: English
• Weight: 232 KB
• Volume: 13
• Category: Article
• ISSN: 0969-7128
• DOI: 10.1038/sj.gt.3302675

✦ Synopsis

Vaccines based on replication-defective adenoviral vectors
are being developed for infectious agents and tumorassociated
antigens. Early work focused on vaccines derived
from a common human serotype of adenovirus, that is,
adenovirus of the serotype 5 (AdHu5). Neutralizing antibodies
against AdHu5 virus, present in a large percentage of
the human population, dampen the efficacy of vaccines
based on this carrier. To circumvent this problem, we
generated vectors derived from chimpanzee adenoviruses.
Here we describe some basic parameters of vectors derived
from chimpanzee adenoviruses C68 and C7, including
growth characteristics, yields of infectious particles, effects
of additional deletions in E3 and E4 and lengths of the
inserted foreign sequence as they relate to the suitability
for their eventual development as vaccine carriers for
clinical use.

✦ Subjects

HIV-1 adenovirus vectors AdHu5 CD8+ T-cell B-cell